{
  "id": 6254461,
  "title": "Rothschild Redburn initiates Tempus AI stock coverage at Neutral",
  "url": "https://urgent.news/2026/09/08/rothschild-redburn-initiates-tempus-ai-stock-coverage-at-neutral",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T08:18:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/rothschild-redburn-initiates-tempus-ai-stock-coverage-at-neutral-93CH-4890960"
  },
  "original_language": "en",
  "account": "Rothschild Redburn has begun covering Tempus AI Inc (NASDAQ:TEM) with a Neutral rating and a price target of $67.00. The firm notes that Tempus AI offers several tests, including the xT-CDx, which is a tumor-informed treatment selection test utilizing tissue samples, and the xR RNA sequencing test. Additionally, Tempus AI provides the xF for tumor-naïve liquid biopsy treatment selection and the xM for tumor-naïve MRD testing. Tempus AI recently acquired Personalis, gaining its NeXT Personal Dx tumor-informed MRD test. Rothschild Redburn views the business primarily as focusing on treatment selection, but acknowledges the data-driven aspect of the company is unique, though they lack insight into long-term growth. Despite recent challenges, Tempus AI reported a 50% revenue growth over the past year. Analysts have raised their earnings estimates for the next few years, with a projected 20% CAGR in revenue from 2026 to 2030. The firm expects Tempus AI to reach free cash flow breakeven by 2027, with an adjusted EBITDA margin of 11% initially, rising to 20% by 2030. Tempus AI's financial results for Q2 2026 showed total revenue of $382.5 million, surpassing H.C. Wainwright's forecast of $390.9 million, but still falling short of the $64 price target that was later lowered to $56. Lastly, several other firms have upgraded Tempus AI's stock rating, including Piper Sandler and Canaccord Genuity, citing acquisition benefits and synergies as key growth factors.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}